tiprankstipranks
Ondine Biomedical Inc. Secures Interim Funding Boost
Company Announcements

Ondine Biomedical Inc. Secures Interim Funding Boost

Ondine Biomedical, Inc. (GB:OBI) has released an update.

Don't Miss Our Christmas Offers:

Ondine Biomedical Inc., a leader in light-activated antimicrobial therapies, has received a C$400,000 interest-free loan from CEO Carolyn Cross to bolster its working capital. Founding shareholders, owning nearly half of the company, have pledged ongoing financial support while Ondine pursues long-term financing to fuel its growth strategies. The company remains optimistic about securing additional funding by the end of the year.

For further insights into GB:OBI stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskOndine Biomedical Launches US Phase 3 Trial for Innovative Antimicrobial Technology
TipRanks UK Auto-Generated NewsdeskOndine Biomedical Gains Investor Attention Post-IPO
TipRanks UK Auto-Generated NewsdeskOndine Biomedical Sees Shift in Voting Rights
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App